Priyanka_S
☆    

2010-03-09 11:46
(5957 d 09:47 ago)

Posting: # 4883
Views: 2,939
 

 EMA: Cmin [Regulatives / Guidelines]

Post reply
Dear all,

The recent Europe guidelines, for steady state studies the parameter Cmin is excluded from Bioequivalence criteria for Immediate relese formulations.

But we want to conduct a steady state study (for Europe) for modified release formulation. Please suggest me the parameter Cmin should require for bioequivalence criteria?
—
Best Regards

Priyanka S
 
Ohlbe
★★★

France,
2010-03-09 12:01
(5957 d 09:33 ago)

@ Priyanka_S
Posting: # 4884
Views: 2,426
 

 EMA: Cmin

Post reply
Dear Priyanka,

Please see this post and Helmut's response.

Regards
Ohlbe
—
Regards
Ohlbe
 
UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
324 visitors (0 registered, 324 guests [including 32 identified bots]).
Forum time: 22:34 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5